[Antiangiogenic Properties of DMAG, An Orally Bioavailable Heat Shock Protein 90 Modulator]
This is now a full text freebie:
clincancerres.aacrjournals.org
Bioavailabillity twice that of 17-AAG, not sure about how much more soluble it is. A lot, definitely, but IPI-504 is supposedly 4000 times more soluble than 17-AAG. I'd guess DMAG is comparable. Both are delivered in saline solution. BTW, in terms of potency, Kosan claims 3-5 times 17-AAG for DMAG, while Infinity claims two times for IPI-504. A look at the ASH abstracts for this year shows a similar schedule for both compounds, but higher doses of IPI-504. Different patients; DMAG abstract is about AML patients, while the IPI-504 abstract is about MM patients. Don't know if that makes a difference in dosing. Side effect profile looked fairly benign in both, and there was activity in the form of several complete responses in the DMAG treated AML patients, whereas little activity was seen for IPI-504 in MM (Infinity acknowledges the need for a combo with velcade for MM). There were cardio events in two of the AML patients at the highest dose, but they already had cardio co-morbidities.
My take is that DMAG and IPI-504 are similar, but that Kosan has a slight lead in development.
Meanwhile, the 17-AAG/Velcade combo is being taken into pivotal trials next year, and looks promising for MM. Though the number of compounds in development for MM is mind-boggling.
myeloma.org
Cheers, Tuck |
